Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.69 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937133 | 0.86 | CYP19A1 (0.73) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL937134 | 0.86 | CYP19A1 (0.73) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL12908981 | 0.85 | CYP19A1 (0.58) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL12908858 | 0.84 | ESR1 (0.70) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL4727358 | 0.82 | CYP19A1 (0.83) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL2973625 | 0.82 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL2973622 | 0.82 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL12944767 | 0.79 | CYP19A1 (0.77) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL177942 | 0.76 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL9726 | 0.76 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | CYP19A1, CYP17A1, CYP21A2 | CYP19A1 1/4885UGT1A4 270/4885PDE4D 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.